BioCardia (NASDAQ:BCDA – Get Free Report) and Prima BioMed (NASDAQ:IMMP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares BioCardia and Prima BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -5,456.14% | -232.75% |
| Prima BioMed | N/A | N/A | N/A |
Earnings & Valuation
This table compares BioCardia and Prima BioMed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $60,000.00 | 183.48 | -$8.23 million | ($0.91) | -1.06 |
| Prima BioMed | $6.69 million | 8.24 | -$39.78 million | N/A | N/A |
BioCardia has higher earnings, but lower revenue than Prima BioMed.
Insider and Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for BioCardia and Prima BioMed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| Prima BioMed | 1 | 2 | 1 | 0 | 2.00 |
BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,484.25%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,369.80%. Given BioCardia’s higher possible upside, equities analysts plainly believe BioCardia is more favorable than Prima BioMed.
Risk and Volatility
BioCardia has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.
Summary
BioCardia beats Prima BioMed on 5 of the 9 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Prima BioMed
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
